TKI Treatment Breaks May Not Impact Outcomes in RCC

Patients with advanced clear cell renal cell carcinoma are “unlikely” to experience a clinically meaningful decrease in overall survival following planned treatment cessation with a tyrosine kinase inhibitor.

Although non-inferiority could not be determined following planned treatment cessation vs conventional continuation with a first-line tyrosine kinase inhibitor, patients with advanced clear cell renal cell carcinoma did not experience a clinically meaningful decrease in survival outcomes, according to data from the phase 2/3 STAR trial.

Read the full story on Cancernetwork.com